Encephalitis: all 284 studies
Page 3 of 3. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.
- Effect of Erythropoietin in Refractory Autoimmune Encephalitis PatientsWithdrawnNCT03004209Phase 4
- Effect of Vigabatrin in Refractory Autoimmune Encephalitis PatientsWithdrawnNCT03003143Not applicable
- Molecular Imaging of Brain Inflammation in Depressive DisordersCompletedNCT02983318
- Postmarketing Surveillance Study for IMOJEV® in Republic of KoreaCompletedNCT02933710
- Epidemiology and Prognosis of Encephalitis in Intensive CareCompletedNCT02906631
- Mechanisms of Auto-immune EncephalitisCompletedNCT02905136
- Etiology of Orphan Community-based Meningitis and Meningo-encephalitis.Status unknownNCT02868593Not applicable
- Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to NivolumabCompletedNCT02856451
- Safety and Immunogenicity of JECEVAX in Young ChildrenCompletedNCT02816554Phase 2
- Antibodies Causing Epilepsy Syndromes: The ACES Study.CompletedNCT02802475
- IL-2 in Refractory Autoimmune EncephalitisCompletedNCT02714959Phase 1/2
- Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) VaccineCompletedNCT02654509Phase 2
- Immunogenicity of Co-administration of Measles and Japanese Encephalitis VaccinesCompletedNCT02643433Phase 4
- Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 VaccineCompletedNCT02602652Not applicable
- Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis VaccineinjCompletedNCT02532569Phase 4
- Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) VaccineStatus unknownNCT02466750Phase 2
- Tick-borne Encephalitis and Positive Borrelial AntibodiesStatus unknownNCT02463942Not applicable
- Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing AreaStatus unknownNCT02443350
- A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese InfantsCompletedNCT02367664Phase 3
- New Study - Humoral Response to Tick-borne Encephalitis Vaccine in ElderlyCompletedNCT02318069Phase 2/3
- Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With EncephalitisCompletedNCT02308982Phase 3
- B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.CompletedNCT02229942Phase 3
- Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of AgeCompletedNCT02186626Phase 1
- 6-year Antibody Check After Third Vaccination Against Japanese EncephalitisCompletedNCT02039440Phase 4
- Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy VolunteersCompletedNCT01984983Phase 1
- Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in ChildrenStatus unknownNCT01954810Phase 4
- The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in HumansCompletedNCT01943305Phase 2
- Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor EncephalitisCompletedNCT01865578Not applicable
- Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese EncephalitisCompletedNCT01856205Phase 2
- Brain Inflammation in Major Depressive Disorder BackgroundCompletedNCT01851356
- Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE VaccineCompletedNCT01815073Phase 4
- Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVacCompletedNCT01710189Phase 4
- Nervous System Infections Among Patients With Febrile SeizureCompletedNCT01694524
- TBE Seropersistence up to 10 Years After First Booster in AdultsCompletedNCT01582698Phase 4
- Immune Response in IXIARO Batch JEV09L37 Recipients Before and After RevaccinationWithdrawnNCT01559831Phase 1
- Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis VaccineCompletedNCT01398540Phase 4
- Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese EncephalitisCompletedNCT01386827Phase 3
- Humoral Response to Tick-borne Encephalitis Vaccine in ElderlyCompletedNCT01361776Phase 2/3
- Safety Surveillance After Immunization With IXIAROCompletedNCT01335412
- Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, TaiwanStatus unknownNCT01163123
- Western Equine Encephalitis Vaccine, InactivatedCompletedNCT01159561Phase 1
- This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly PopulationCompletedNCT01158599Phase 4
- Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in KoreaCompletedNCT01150942Phase 3
- An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBECompletedNCT01106482Phase 4
- Postencephalitic Symptoms After Tick Borne EncephalitisStatus unknownNCT00941590
- Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDRStatus unknownNCT00938379Phase 3
- Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus VaccineStatus unknownNCT00890422Phase 2
- Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis VaccinationCompletedNCT00804219Phase 4
- Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in ToddlersCompletedNCT00694460Phase 2
- Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen EncephalitisStatus unknownNCT00545493Phase 2/3
- TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)CompletedNCT00503529Phase 4
- Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization ScheduleCompletedNCT00460486Phase 3
- Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five YearsCompletedNCT00452621Phase 4
- Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and AdultsCompletedNCT00387634Phase 4
- Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal FluidCompletedNCT00381433Phase 1
- Treatment of Cerebral Toxoplasmosis in HIV/AIDSCompletedNCT00367081Phase 4
- Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for AdultsCompletedNCT00311493Phase 4
- Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy ChildrenCompletedNCT00311441Phase 4
- A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal EncephalitisCompletedNCT00259805Phase 1
- Treatment of Japanese EncephalitisStatus unknownNCT00216268Phase 2
- Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in ChildrenCompletedNCT00163618
- Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)CompletedNCT00163540Phase 4
- TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)CompletedNCT00161967Phase 4
- Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 YearsCompletedNCT00161954Phase 4
- FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsCompletedNCT00161889Phase 2
- FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 YearsCompletedNCT00161876Phase 3
- Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 YearsCompletedNCT00161863Phase 3
- FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsCompletedNCT00161850Phase 2
- Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPURCompletedNCT00161824Phase 3
- Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.CompletedNCT00161798Phase 2
- Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 YearsCompletedNCT00161785Phase 4
- Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.CompletedNCT00161772Phase 2
- Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 YearsCompletedNCT00161746Phase 2/3
- Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy AdultsCompletedNCT00118924Phase 1
- Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus VaccineWithdrawnNCT00109304Phase 1
- Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy AdultsCompletedNCT00094718Phase 1
- Natural History of West Nile Virus InfectionCompletedNCT00069303
- IVIG - West Nile Encephalitis: Safety and EfficacyCompletedNCT00068055Phase 1/2
- Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of RelapseCompletedNCT00002064Not applicable
- A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-SulfadiazineCompletedNCT00001994Not applicable
- Structure of the Herpes Simplex Virus ReceptorCompletedNCT00001648
- Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic EncephalitisCompletedNCT00000794Phase 2
- A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDSCompletedNCT00000674Not applicable
- A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii InfectionCompletedNCT00000666Not applicable